Orange Biomed
A healthcare startup with cutting-edge diabetes management technology.
A healthcare startup with cutting-edge diabetes management technology.
Orange Biomed is a healthcare startup with a strong focus on cutting-edge diabetes management technology. Currently, the company is conducting research studies for OBM rapid A1c at Seoul Asan Medical Center, which is South Korea's largest hospital. Moreover, it is important to note that this medical center is backed by the Hyundai group, one of Korea's largest conglomerates with a robust presence in the healthcare sector.
Founded in 2021, Orange Biomed received a significant boost with a KRW1.00B Seed Round investment on 10 January 2023. This investment was led by Intops Investment, showcasing the confidence that notable investors have in the company's vision and technology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | KRW1.00B | 1 |
|
10 Jan 2023 |
| Seed Round | $2.60M | - | 29 Dec 2022 | |
| Seed Round | KRW1.60B | 2 |
|
10 Aug 2022 |
| Pre Seed Round | $500.00K | - | 17 Dec 2021 |
No recent news or press coverage available for Orange Biomed.
-logo.jpg){kind=logo}
--logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.